Description: LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Home Page: www.livanova.com
LIVN Technical Analysis
20 Eastbourne Terrace
London,
W2 6LG
United Kingdom
Phone:
44 20 3325 0660
Officers
| Name | Title |
|---|---|
| Mr. Damien McDonald | CEO & Director |
| Mr. Alex Shvartsburg | Chief Financial Officer |
| Ms. Trui Hebbelinck | Chief HR Officer |
| Ms. Keyna Pidcock Skeffington | Sr. VP, Special Advisor & Exec. Officer |
| Mr. Marco Dolci | Pres of Cardiopulmonary Bus. Unit |
| Lindsey Little | Sr. Director of Investor Relations |
| Mr. Michael Hutchinson | Sr. VP, Chief Legal Officer and Company Sec. |
| Deanna Wilke | VP of Corp. Communications |
| Mr. Matthew Joseph Dodds III | Sr. VP of Corp. Devel. |
| Dr. Bryan D. Olin Ph.D. | Sr. VP & Head of Product Devel. - Neuromodulation |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 24.4499 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.588 |
| Price-to-Sales TTM: | 2.8203 |
| IPO Date: | 1993-02-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 3000 |